Venture Kick

HeroSupport is a medical device manufacturing company that transforms imaging and/or treatment tables into personalized solutions. The company was founded in 2019 and is headquartered in Veyrier, Geneva.

CERN is a prominent particle-physics laboratory located in Geneva, Switzerland, established in 1954. It serves as the European organization for nuclear research, where physicists and engineers investigate the fundamental structure of the universe. CERN specializes in providing advanced particle accelerators and detectors, which are essential for high-energy physics research. These accelerators propel beams of particles to high energies, enabling collisions that are then analyzed by sophisticated detectors to explore the basic constituents of matter and the forces between them. Governed by 22 member states, CERN represents a significant collaborative effort in scientific research, focusing on the fundamental questions of physics and contributing to the global understanding of the universe.

SightIn Health develops artificial intelligence-powered software for using portable ultrasound. It provides image analytics, usage guidance, and interpretation of patient's diagnosis. SightIn Health was founded in 2021 and is based in Geneva, Switzerland.

Exomotion develops robotics-based transporter devices designed to facilitate omnidirectional movement. Its devices are electronic movement systems that integrate electrical boards with motion sensors and a wheeled motion mechanism that enables the board to go in any direction and rotate immediately allowing for improved user experience. It rethinks the concept of e-mobility, bringing omnidirectionality and safety to the mix. Exomotion was founded in 2018 and is based in Plan-les-ouates, Geneve.

Terapet was founded at CERN by two physicists – Christina Vallgren and Marcus Palm – along with Professor Raymond Miralbell from the Geneva University Hospitals (HUG). They have already proven the feasibility of their concept and are now developing an initial version for market launch.

Endotelix is a Swiss biotech start-up and a spin-off from the University of Geneva, focused on developing innovative solutions for Antiphospholipid Syndrome. The company specializes in creating fast, sensitive, and reliable diagnostic tests and treatment options aimed at detecting circulating antibodies associated with this condition. Endotelix primarily targets the healthcare needs of pregnant women and adolescent children, providing research tools and therapies that assist healthcare professionals in reducing pregnancy-related complications and enhancing overall healthcare outcomes.

Shematic, founded in Geneva in 2018, specializes in providing customized electric powertrains for a variety of vehicle manufacturers, including those in the passenger, leisure, and commercial sectors. The company aims to enhance electric mobility by delivering tailored electric solutions that cater to power outputs ranging from 1kW to 500kW. With extensive expertise in electric mobility, Shematic also offers consulting services to assist clients in developing and implementing production processes, as well as designing and producing approved engines and battery packs. This diverse skill set positions Shematic as a comprehensive partner for customers seeking effective traction systems and electrical networks for their vehicles.

Endotelix is a Swiss biotech start-up and a spin-off from the University of Geneva, focused on developing innovative solutions for Antiphospholipid Syndrome. The company specializes in creating fast, sensitive, and reliable diagnostic tests and treatment options aimed at detecting circulating antibodies associated with this condition. Endotelix primarily targets the healthcare needs of pregnant women and adolescent children, providing research tools and therapies that assist healthcare professionals in reducing pregnancy-related complications and enhancing overall healthcare outcomes.

ALAnostics is a biopharmaceutical company that specializes in oncodiagnostics, originating as a spin-off from the University of Geneva. The company focuses on developing innovative tumour painting technology designed to assist surgeons in the real-time identification and removal of breast cancer during surgery. By utilizing nanomedicines for fluorescence-guided surgery, along with 5-ALA prodrugs for photodynamic therapy and light-activated antimicrobials, ALAnostics aims to enhance the accuracy of tumor removal, ultimately improving patient outcomes and saving lives.

EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

Exomotion develops robotics-based transporter devices designed to facilitate omnidirectional movement. Its devices are electronic movement systems that integrate electrical boards with motion sensors and a wheeled motion mechanism that enables the board to go in any direction and rotate immediately allowing for improved user experience. It rethinks the concept of e-mobility, bringing omnidirectionality and safety to the mix. Exomotion was founded in 2018 and is based in Plan-les-ouates, Geneve.

EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

ABCDx SA is a Swiss company founded in 2014 that specializes in the development, validation, and application of biomarker tests for brain injury treatment. The company focuses on creating biomarker panels designed to identify and diagnose patients at risk for severe long-term complications resulting from conditions such as traumatic brain injuries, strokes, and post-stroke infections. The founders are prominent researchers from the University of Geneva and the Vall d’Hebron Research Institute, bringing significant expertise in biomarker discovery and clinical application. They are complemented by a third founder with extensive experience in the diagnostic and pharmaceutical industries, enhancing the company’s capacity to innovate in brain health diagnostics.

EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

the fair traveller operates an online community platform designed for travelers, enabling users to share reviews and comments about various establishments such as restaurants, cafes, hotels, and shops. Founded in 2015 and based in Geneva, Switzerland, the platform emphasizes the importance of environmental and social engagements in the travel experience. It aims to connect individuals with sustainable options, referred to as "fairspots," where businesses actively participate in promoting social and environmental responsibility. By facilitating access to these authentic venues, the fair traveller encourages users to make informed choices that contribute to sustainable development, enhancing the overall impact of their travel.

Includeed is a consultancy and innovative solution provider focused on promoting diversity and inclusion, particularly in relation to gender issues. Founded in 2015 and based in Les Acacias, Switzerland, the company operates a platform that allows employees, job seekers, and customers to review and share experiences, ask questions, suggest solutions, and request companies to disclose information regarding diversity and equal opportunities. Includeed's programs extend across several locations, including Geneva, Zurich, Paris, and Lyon, aiming to foster dialogue and transparency in workplace practices related to diversity.

Tourmaline is an interactive studio that focuses on digital media and game production. It specialize in hybrid products, including connected objects, multi device setups, and paper video games. Tourmaline was launched by Camille Attard in 2015. It is operated from Geneve, Switzerland.

Plair SA specializes in the development and manufacturing of advanced systems for monitoring environmental conditions, particularly focusing on airborne particles. Founded in 2014 and based in Geneva, Switzerland, the company offers a range of innovative instruments, including the Particle Analyzer PA-300, which provides real-time detection, identification, and classification of fine particles in the air. This device can differentiate various entities such as pollen species, organic particles like fungal spores, and pollutants including polycyclic aromatic hydrocarbons. Additionally, Plair SA's Rapid-E and Rapid-C instruments utilize cutting-edge technologies like laser-induced fluorescence and light scattering for comprehensive analysis of aerosol particles. The company's solutions cater to applications in airborne allergen monitoring, air quality assessment, and bioaerosol analysis, enabling a deeper understanding of atmospheric aerosol concentrations. Plair SA is a spin-off from the University of Geneva, reflecting its strong academic foundation.

Plair SA specializes in the development and manufacturing of advanced systems for monitoring environmental conditions, particularly focusing on airborne particles. Founded in 2014 and based in Geneva, Switzerland, the company offers a range of innovative instruments, including the Particle Analyzer PA-300, which provides real-time detection, identification, and classification of fine particles in the air. This device can differentiate various entities such as pollen species, organic particles like fungal spores, and pollutants including polycyclic aromatic hydrocarbons. Additionally, Plair SA's Rapid-E and Rapid-C instruments utilize cutting-edge technologies like laser-induced fluorescence and light scattering for comprehensive analysis of aerosol particles. The company's solutions cater to applications in airborne allergen monitoring, air quality assessment, and bioaerosol analysis, enabling a deeper understanding of atmospheric aerosol concentrations. Plair SA is a spin-off from the University of Geneva, reflecting its strong academic foundation.

Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

Andrew Alliance S.A., founded in 2011 and based in Geneva, Switzerland, specializes in the development and commercialization of robotic solutions for the life sciences sector. The company offers a range of products designed to enhance laboratory efficiency and accuracy in liquid handling. Its key offerings include OneLab, a user-friendly graphical interface for liquid handling tasks; Andrew+, a robotic pipetting system utilizing conventional electronic pipettes; and Andrew, a portable robot that operates unattended manual pipettes. Additionally, Andrew Assistant is a software tool for designing and documenting biological protocols requiring precise liquid handling. By integrating advanced robotics, innovative hardware, and software algorithms, Andrew Alliance aims to transform laboratory workflows that currently rely on manual processes. The company sells its products directly and through a network of distributors in Switzerland and internationally. Andrew Alliance's operations are supported by strategic initiatives such as VentureKick and the EUREKA EUROSTARS program, ensuring the development of cutting-edge technology tailored to the needs of biologists and technicians.

Gourmetiz is an online platform that connects food producers to a range of consumers. The company was founded in 2011 and is headquartered in Geneve, Europe.

TheFabric Physical Computing, founded in 2011 by Dr. Xavier Righetti and based in Geneva, Switzerland, focuses on the design and development of interactive solutions that integrate both hardware and software. The company specializes in creating tangible systems using open hardware and graphical interfaces through open source software. Its offerings include low-end wireless home automation modules, aimed at enhancing energy efficiency and comfort for clients, while also supporting their growth and revenue generation. TheFabric combines innovation in physical computing with practical applications to meet the needs of a diverse clientele.

Neurix SA is a Swiss biotechnology company based in Geneva, established in 2011, that specializes in in vitro research and development for neurotropic drugs. The company provides a range of drug discovery services, including the creation of innovative 3D neural tissues known as MiniBrains, which are generated from human or murine pluripotent stem cells. These services facilitate the development of disease models and enable researchers to conduct drug screening and lead compound validation more efficiently. Neurix's offerings also encompass various assessments related to drug efficacy on tumor growth, motility, and metastasis, allowing scientists to achieve improved research outcomes through a streamlined workflow.

Andrew Alliance S.A., founded in 2011 and based in Geneva, Switzerland, specializes in the development and commercialization of robotic solutions for the life sciences sector. The company offers a range of products designed to enhance laboratory efficiency and accuracy in liquid handling. Its key offerings include OneLab, a user-friendly graphical interface for liquid handling tasks; Andrew+, a robotic pipetting system utilizing conventional electronic pipettes; and Andrew, a portable robot that operates unattended manual pipettes. Additionally, Andrew Assistant is a software tool for designing and documenting biological protocols requiring precise liquid handling. By integrating advanced robotics, innovative hardware, and software algorithms, Andrew Alliance aims to transform laboratory workflows that currently rely on manual processes. The company sells its products directly and through a network of distributors in Switzerland and internationally. Andrew Alliance's operations are supported by strategic initiatives such as VentureKick and the EUREKA EUROSTARS program, ensuring the development of cutting-edge technology tailored to the needs of biologists and technicians.

ecaVert Ltd, founded in 2010 by engineers Nicolas Ecabert and Sylvain Melis, specializes in engineering and consulting services focused on water and soil protection. The company emerged from their studies at the Haute École du Paysage, d'Ingénierie et d'Architecture in Geneva, where they aimed to commercialize innovative solutions developed in collaboration with Professor Pascal Boivin, who oversees the soils and substrates laboratory at the institution. ecaVert is known for its vertical green biobed technology, designed for water treatment. This product promotes the development of beneficial soil organisms that enhance soil structure, recycle organic material, and break down rocks to release essential nutrients, thereby providing effective infrastructure for environmental protection.

Gourmetiz is an online platform that connects food producers to a range of consumers. The company was founded in 2011 and is headquartered in Geneve, Europe.

Stemergie is a spin-off company from the Geneva University Hospital (HUG) and the University of Geneva (UNIGE) and was incorporated in 2009. Stemergie develops treatments and diagnostics for cancers by targeting cancer-initiating cells (CIC), the roots of cancer. Stemergie's CIC based technology platform allows the identification, validation and development of treatments against brain CIC. With its proprietary methodology Stemergie is able to identify, isolate and enrich CIC independently of any marker. Stemergie plans to translate this technology to further types of CIC, in order to treat and diagnose melanoma as well as further oncology indications. Stemergie has identified and validated molecules that specifically eradicate brain CIC. These effective treatments targeting the roots of cancer in combination with the current standard treatments have a high potential to increase the survival rate of the brain tumor patient in the future.